Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
PhenoMiner Database Result        View data table  |  Download data table  |  View expanded data table        


Generate Chart For    
    (Chart displayed below)
Rat Strains

{{sample.term}}
Measurement Methods

{{method.term}}
Age

{{ageRange}}
Experimental Conditions

     {{ cond }}

Minimum Value:    Maximum Value:    Sex:


 
Options:  View chart  |  Download data table  |  View expanded data table
# of AnimalsPhenotypeStrainSexValueUnitsConditionsRecord IDCondition 1aCondition 1bCondition 2aCondition 2bCondition 2cCondition 3aCondition 3bCondition 3c
48mammary tumor numberSPRD/Ztmfemale11.237,12-dimethyltetraphene (DMBA) (65 mg/kg) 113407,12-dimethyltetraphene (DMBA) (65 mg/kg)
46mammary tumor numberSPRD.WKY-(D18Wox8-D18Rat44)/Ibmmfemale7.617,12-dimethyltetraphene (DMBA) (65 mg/kg) 113427,12-dimethyltetraphene (DMBA) (65 mg/kg)
14mammary tumor numberSPRD.WKY-(D5Rat190-D5Rat114)/Ibmmfemale3.937,12-dimethyltetraphene (DMBA) (65 mg/kg) 113417,12-dimethyltetraphene (DMBA) (65 mg/kg)
7mammary tumor numberCOP/CrCrlfemale0.117 beta-estradiol (27.5 mg) (for 196 days)1137017 beta-estradiol (27.5 mg) (for 196 days)
5mammary tumor numberCOP/CrCrlfemale0control condition11369control condition
21mammary tumor numberACI/SegHsdfemale717 beta-estradiol (27.5 mg) (for 196 days)1136817 beta-estradiol (27.5 mg) (for 196 days)
4mammary tumor numberACI/SegHsdfemale0control condition11367control condition
12mammary tumor numberACI.COP-(D10Mgh8-D10Rat4)/Shulfemale4.817 beta-estradiol (27.5 mg) (for 196 days)1136617 beta-estradiol (27.5 mg) (for 196 days)
3mammary tumor numberACI.COP-(D10Mgh8-D10Rat4)/Shulfemale0control condition11365control condition
17mammary tumor numberACI.COP-(D3Rat130-D3Rat114)/Shulfemale4.517 beta-estradiol (27.5 mg) (for 196 days)1136417 beta-estradiol (27.5 mg) (for 196 days)
3mammary tumor numberACI.COP-(D3Rat130-D3Rat114)/Shulfemale0control condition11363control condition
8mammary tumor numberACI.COP-(D3Mgh16-D3Rat119)/Shulfemale4.317 beta-estradiol (27.5 mg) (for 196 days)1136217 beta-estradiol (27.5 mg) (for 196 days)
3mammary tumor numberACI.COP-(D3Mgh16-D3Rat119)/Shulfemale0control condition11361control condition
17mammary tumor numberACI.COP-(D6Rat80-D6Rat146)/Shulfemale2.417 beta-estradiol (27.5 mg) (for 196 days)1136017 beta-estradiol (27.5 mg) (for 196 days)
3mammary tumor numberACI.COP-(D6Rat80-D6Rat146)/Shulfemale0control condition11359control condition
20mammary tumor numberACI/SegHsdfemale5.617 beta-estradiol (27.5 mg) (between 99 and 197 days)1137717 beta-estradiol (27.5 mg) (between 99 and 197 days)
14mammary tumor numberSS-Chr 19BN/Mcwifemale8.797,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)115077,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
13mammary tumor numberSS-Chr 16BN/Mcwifemale6.317,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)115047,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
13mammary tumor numberSS-Chr 13BN/Mcwifemale5.337,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)115017,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
40mammary tumor numberSS/JrHsdMcwifemale2.457,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)114887,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
14mammary tumor numberSS.BN-(D13Hmgc64-RN34_13048990782)/Mcwifemale4.867,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)655737,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
14ratio of deaths related to DMBA toxicity to total study population during a period of timeSS.BN-(D6Rat149-D6Arb3)/Mcwifemale57%7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)655757,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
15ratio of deaths related to DMBA toxicity to total study population during a period of timeSS.BN-(D6Rat149-D6Rat18)/Mcwifemale80%7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)655767,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
15ratio of deaths related to DMBA toxicity to total study population during a period of timeSS.BN-(D6Rat149-D6Got171)/Mcwifemale40%7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)655777,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
20ratio of deaths related to DMBA toxicity to total study population during a period of timeSS-Chr 6BN/Mcwifemale95%7,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)655787,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
14mammary tumor numberSS.BN-(D6Rat149-D6Arb3)/Mcwifemale4.777,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)655717,12-dimethyltetraphene (DMBA) (65 mg/kg) (for 105 days)
17mammary tumor numberWKY/NHsdfemale07,12-dimethyltetraphene (DMBA) (65 mg/kg) 117417,12-dimethyltetraphene (DMBA) (65 mg/kg)
21mammary tumor numberWF/NHsdfemale7.37,12-dimethyltetraphene (DMBA) (65 mg/kg) 117427,12-dimethyltetraphene (DMBA) (65 mg/kg)
30mammary tumor numberWF/NHsdfemale8.17,12-dimethyltetraphene (DMBA) (65 mg/kg) 117467,12-dimethyltetraphene (DMBA) (65 mg/kg)
16mammary tumor numberCOP/OlaHsdfemale0.257,12-dimethyltetraphene (DMBA) (65 mg/kg) 117477,12-dimethyltetraphene (DMBA) (65 mg/kg)
29mammary tumor numberWF/NHsdfemale6.37,12-dimethyltetraphene (DMBA) (65 mg/kg) 701677,12-dimethyltetraphene (DMBA) (65 mg/kg)
19mammary tumor numberWF.COP-(D2Mit29-D2Rat201)/Uwmfemale1.57,12-dimethyltetraphene (DMBA) (65 mg/kg) 701687,12-dimethyltetraphene (DMBA) (65 mg/kg)
8percentage of study population developing unilateral renal agenesis during a period of timeF344/Jclmale0%control condition106884control condition
8percentage of study population developing subcutaneous tumors during a period of timeF344/Jclmale38%control condition106886control condition
12percentage of study population developing subcutaneous tumors during a period of timeACI/SegHsdmale0%control condition106887control condition
12percentage of study population developing unilateral renal agenesis during a period of timeACI/SegHsdmale24%control condition106885control condition
53mammary tumor numberWFfemale3.627,12-dimethyltetraphene (DMBA) (65 mg/kg) (between 126 and 140 days)661007,12-dimethyltetraphene (DMBA) (65 mg/kg) (between 126 and 140 days)
8age at time of deathSS/Jrnot specified108dcontrolled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 66 and 68 days)69608controlled sodium content diet (0.3 %) (between 10 and 12 days)controlled sodium content diet (2 %) (between 66 and 68 days)
8age at time of deathSS.SHR-(D9Mco72-D9Mco105)/Mconot specified146dcontrolled sodium content diet (0.3 %) (between 10 and 12 days) then controlled sodium content diet (2 %) (between 104 and 106 days)69610controlled sodium content diet (0.3 %) (between 10 and 12 days)controlled sodium content diet (2 %) (between 104 and 106 days)
20ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of timeDA/ZtmKiniboth0%myelin oligodendrocyte glycoprotein (20 ug/200 ul) 68125myelin oligodendrocyte glycoprotein (20 ug/200 ul)
19ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of timeDA.PVG.1AV1-(D4Got126-D4Got136)both0%myelin oligodendrocyte glycoprotein (20 ug/200 ul) 68127myelin oligodendrocyte glycoprotein (20 ug/200 ul)
23ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of timeDA/ZtmKiniboth61%myelin oligodendrocyte glycoprotein (20 ug/200 ul) 68129myelin oligodendrocyte glycoprotein (20 ug/200 ul)
21ratio of deaths related to experimental autoimmune encephalomyelitis to total study population during a period of timeDA.PVG.1AV1-(D4Got126-D4Got136)both24%myelin oligodendrocyte glycoprotein (20 ug/200 ul) 68131myelin oligodendrocyte glycoprotein (20 ug/200 ul)
11percentage of study population developing liver tumors during a period of timeF344/NRrrcnot specified100%controlled 3-methyl-4'-dimethylaminoazobenzene content diet (0.06 %) (for 140 days)68164controlled 3-methyl-4'-dimethylaminoazobenzene content diet (0.06 %) (for 140 days)
5percentage of study population developing liver tumors during a period of timeDRH/Seacnot specified0%controlled 3-methyl-4'-dimethylaminoazobenzene content diet (0.06 %) (for 140 days)68165controlled 3-methyl-4'-dimethylaminoazobenzene content diet (0.06 %) (for 140 days)
9percentage of study population developing hepatocellular carcinoma during a period of timeF344/NHsdnot specified89%N-nitrosodiethylamine (150 mg/kg) then 2-acetamidofluorene (0.02 %) (for 490 days) then partial hepatectomy96757N-nitrosodiethylamine (150 mg/kg) 2-acetamidofluorene (0.02 %) (for 490 days)partial hepatectomy
10percentage of study population developing hepatocellular carcinoma during a period of timeBN/SsNHsdnot specified10%N-nitrosodiethylamine (150 mg/kg) then 2-acetamidofluorene (0.02 %) (for 490 days) then partial hepatectomy96758N-nitrosodiethylamine (150 mg/kg) 2-acetamidofluorene (0.02 %) (for 490 days)partial hepatectomy
96percentage of study population developing unilateral renal agenesis during a period of timeACI/SegHsdfemale13.5%control condition69372control condition
36percentage of study population developing unilateral renal agenesis during a period of timeBN/SsNHsdfemale0%control condition69373control condition
87percentage of study population developing unilateral renal agenesis during a period of timeACI/SegHsdmale5.7%control condition69374control condition
43percentage of study population developing unilateral renal agenesis during a period of timeBN/SsNHsdmale0%control condition69375control condition
20squamous cell carcinoma of the tongue tumor numberWF/Kgaboth1controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)70315controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)
23squamous cell carcinoma of the tongue tumor numberWF.DA-(D19Mit1-D19Mit6)/Kopboth1.65controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)70316controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)
20squamous cell carcinoma of the tongue tumor numberDA/Slcboth2.35controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)70317controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)
20number of squamous cell tumors of the tongue with diameter greater than 3 mmWF/Kgaboth0.35controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)70318controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)
23number of squamous cell tumors of the tongue with diameter greater than 3 mmWF.DA-(D19Mit1-D19Mit6)/Kopboth0.78controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)70319controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)
20number of squamous cell tumors of the tongue with diameter greater than 3 mmDA/Slcboth1.6controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)70320controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)
20squamous cell carcinoma of the tongue maximum tumor diameterWF/Kgaboth1.15mmcontrolled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)70321controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)
23squamous cell carcinoma of the tongue maximum tumor diameterWF.DA-(D19Mit1-D19Mit6)/Kopboth3.17mmcontrolled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)70322controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)
20squamous cell carcinoma of the tongue maximum tumor diameterDA/Slcboth10.35mmcontrolled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)70323controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)
20squamous cell carcinoma of the head and neck tumor numberWF/Kgaboth2.75controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)70324controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)
23squamous cell carcinoma of the head and neck tumor numberWF.DA-(D19Mit1-D19Mit6)/Kopboth4.75controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)70325controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)
20squamous cell carcinoma of the head and neck tumor numberDA/Slcboth5.55controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)70326controlled 4-nitroquinoline N-oxide content drinking water (10 mg/l) (for 180 days)
47number of squamous cell tumors of the tongue with diameter greater than 5 mmDA/Slcboth1.17controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)70393controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)
50number of squamous cell tumors of the tongue with diameter greater than 5 mmWFboth0.04controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)70394controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)
47squamous cell carcinoma of the tongue tumor numberDA/Slcboth1.49controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)70395controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)
50squamous cell carcinoma of the tongue tumor numberWFboth0.42controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)70396controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)
47squamous cell carcinoma of the tongue maximum tumor diameterDA/Slcboth12.77mmcontrolled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)70397controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)
50squamous cell carcinoma of the tongue maximum tumor diameterWFboth1.18mmcontrolled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)70398controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)
47non-tongue squamous cell carcinoma of the head and neck tumor numberDA/Slcboth1.83controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)70399controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)
50non-tongue squamous cell carcinoma of the head and neck tumor numberWFboth0.78controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)70400controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)
47squamous cell carcinoma of the head and neck tumor numberDA/Slcboth3.34controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)70401controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)
50squamous cell carcinoma of the head and neck tumor numberWFboth1.26controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)70402controlled 4-nitroquinoline N-oxide content drinking water (0.001 %) (for 0.1 hours)
22percentage of study population developing stomach tumors during a period of timeBUF/NacJclnot specified14%controlled N-methyl-N'-nitro-N-nitrosoguanidine content drinking water (83 mg/l) (for 224 days)84752controlled N-methyl-N'-nitro-N-nitrosoguanidine content drinking water (83 mg/l) (for 224 days)
21percentage of study population developing stomach tumors during a period of timeACI/NJclnot specified76%controlled N-methyl-N'-nitro-N-nitrosoguanidine content drinking water (83 mg/l) (for 224 days)84753controlled N-methyl-N'-nitro-N-nitrosoguanidine content drinking water (83 mg/l) (for 224 days)
57percentage of study population displaying trigeminal nerve neurilemmomas at a point in timeBDIX/Ztemale55%N-ethyl-N-nitrosourea (80 ug/g) 98097N-ethyl-N-nitrosourea (80 ug/g)
77post-insult time of deathBDIX.BDIV-D10Got1-D10Rat45/Zteboth239dN-ethyl-N-nitrosourea (80 ug/g) 98176N-ethyl-N-nitrosourea (80 ug/g)
109percentage of study population displaying trigeminal nerve neurilemmomas at a point in timeBDIX/Ztefemale49%N-ethyl-N-nitrosourea (80 ug/g) 98177N-ethyl-N-nitrosourea (80 ug/g)
75percentage of study population displaying trigeminal nerve neurilemmomas at a point in timeBDIX.BDIV-D10Mit3-D10Mgh16/Ztefemale7.9%N-ethyl-N-nitrosourea (80 ug/g) 98178N-ethyl-N-nitrosourea (80 ug/g)
77percentage of study population displaying trigeminal nerve neurilemmomas at a point in timeBDIX.BDIV-D10Got1-D10Rat45/Ztefemale22.5%N-ethyl-N-nitrosourea (80 ug/g) 98179N-ethyl-N-nitrosourea (80 ug/g)
57post-insult time of deathBDIX/Ztemale197dN-ethyl-N-nitrosourea (80 ug/g) 98091N-ethyl-N-nitrosourea (80 ug/g)
52post-insult time of deathBDIX/Ztefemale214dN-ethyl-N-nitrosourea (80 ug/g) 98092N-ethyl-N-nitrosourea (80 ug/g)
38post-insult time of deathBDIX.BDIV-D10Mit3-D10Mgh16/Ztemale241dN-ethyl-N-nitrosourea (80 ug/g) 98093N-ethyl-N-nitrosourea (80 ug/g)
37post-insult time of deathBDIX.BDIV-D10Mit3-D10Mgh16/Ztefemale272dN-ethyl-N-nitrosourea (80 ug/g) 98094N-ethyl-N-nitrosourea (80 ug/g)
37post-insult time of deathBDIX.BDIV-D10Got1-D10Rat45/Ztemale229dN-ethyl-N-nitrosourea (80 ug/g) 98095N-ethyl-N-nitrosourea (80 ug/g)
40post-insult time of deathBDIX.BDIV-D10Got1-D10Rat45/Ztefemale348dN-ethyl-N-nitrosourea (80 ug/g) 98096N-ethyl-N-nitrosourea (80 ug/g)
52percentage of study population displaying trigeminal nerve neurilemmomas at a point in timeBDIX/Ztefemale41.5%N-ethyl-N-nitrosourea (80 ug/g) 98098N-ethyl-N-nitrosourea (80 ug/g)
38percentage of study population displaying trigeminal nerve neurilemmomas at a point in timeBDIX.BDIV-D10Mit3-D10Mgh16/Ztemale13.9%N-ethyl-N-nitrosourea (80 ug/g) 98099N-ethyl-N-nitrosourea (80 ug/g)
37percentage of study population displaying trigeminal nerve neurilemmomas at a point in timeBDIX.BDIV-D10Mit3-D10Mgh16/Ztefemale2.9%N-ethyl-N-nitrosourea (80 ug/g) 98100N-ethyl-N-nitrosourea (80 ug/g)
37percentage of study population displaying trigeminal nerve neurilemmomas at a point in timeBDIX.BDIV-D10Got1-D10Rat45/Ztemale32.7%N-ethyl-N-nitrosourea (80 ug/g) 98101N-ethyl-N-nitrosourea (80 ug/g)
40percentage of study population displaying trigeminal nerve neurilemmomas at a point in timeBDIX.BDIV-D10Got1-D10Rat45/Ztefemale17.2%N-ethyl-N-nitrosourea (80 ug/g) 98102N-ethyl-N-nitrosourea (80 ug/g)
109post-insult time of deathBDIX/Zteboth201dN-ethyl-N-nitrosourea (80 ug/g) 98174N-ethyl-N-nitrosourea (80 ug/g)
75post-insult time of deathBDIX.BDIV-D10Mit3-D10Mgh16/Zteboth247dN-ethyl-N-nitrosourea (80 ug/g) 98175N-ethyl-N-nitrosourea (80 ug/g)
100post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumorsBDIX.BDIV-D6Mit1-D6Mgh2/Zteboth234dN-ethyl-N-nitrosourea (80 mg/kg) 98130N-ethyl-N-nitrosourea (80 mg/kg)
57post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumorsBDIXmale197dN-ethyl-N-nitrosourea (80 mg/kg) 98125N-ethyl-N-nitrosourea (80 mg/kg)
52post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumorsBDIXfemale214dN-ethyl-N-nitrosourea (80 mg/kg) 98126N-ethyl-N-nitrosourea (80 mg/kg)
109post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumorsBDIXboth201dN-ethyl-N-nitrosourea (80 mg/kg) 98127N-ethyl-N-nitrosourea (80 mg/kg)
51post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumorsBDIX.BDIV-D6Mit1-D6Mgh2/Ztemale224dN-ethyl-N-nitrosourea (80 mg/kg) 98128N-ethyl-N-nitrosourea (80 mg/kg)
49post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumorsBDIX.BDIV-D6Mit1-D6Mgh2/Ztefemale279dN-ethyl-N-nitrosourea (80 mg/kg) 98129N-ethyl-N-nitrosourea (80 mg/kg)
39post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumorsBDIX.BDIV-D6Rat132-D6Mgh3/Ztemale231dN-ethyl-N-nitrosourea (80 mg/kg) 98131N-ethyl-N-nitrosourea (80 mg/kg)
47post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumorsBDIX.BDIV-D6Rat132-D6Mgh3/Ztefemale235dN-ethyl-N-nitrosourea (80 mg/kg) 98132N-ethyl-N-nitrosourea (80 mg/kg)
86post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumorsBDIX.BDIV-D6Rat132-D6Mgh3/Zteboth232dN-ethyl-N-nitrosourea (80 mg/kg) 98133N-ethyl-N-nitrosourea (80 mg/kg)
24post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumorsBDIX.BDIV-D6Rat132-D6Rat229/Zteboth227dN-ethyl-N-nitrosourea (80 mg/kg) 98135N-ethyl-N-nitrosourea (80 mg/kg)
56post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumorsBDIX.BDIV-D6Mit8-D6Rat229/Ztemale222dN-ethyl-N-nitrosourea (80 mg/kg) 98136N-ethyl-N-nitrosourea (80 mg/kg)
62post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumorsBDIX.BDIV-D6Mit8-D6Rat229/Ztefemale236dN-ethyl-N-nitrosourea (80 mg/kg) 98137N-ethyl-N-nitrosourea (80 mg/kg)
118post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumorsBDIX.BDIV-D6Mit8-D6Rat229/Zteboth228dN-ethyl-N-nitrosourea (80 mg/kg) 98138N-ethyl-N-nitrosourea (80 mg/kg)
63post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumorsBDIVmale593dN-ethyl-N-nitrosourea (80 mg/kg) 98139N-ethyl-N-nitrosourea (80 mg/kg)
49post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumorsBDIVfemale482dN-ethyl-N-nitrosourea (80 mg/kg) 98140N-ethyl-N-nitrosourea (80 mg/kg)
112post-insult time of death due to ENU-induced malignant peripheral nerve sheath tumorsBDIVboth593dN-ethyl-N-nitrosourea (80 mg/kg) 98141N-ethyl-N-nitrosourea (80 mg/kg)
15post-insult time of deathBDIX/OrlCrlmale82.7dDHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days)111117DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)
14post-insult time of deathBDIX/OrlCrlmale77.4dDHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then Thymosin alpha-1 (200 ug/kg) (for 4 days)111118DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)Thymosin alpha-1 (200 ug/kg) (for 4 days)
15post-insult time of deathBDIX/OrlCrlmale83.1dDHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then interleukin-2 (75000 U/d) (for 4 days)111119DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)interleukin-2 (75000 U/d) (for 4 days)
15post-insult time of deathBDIX/OrlCrlmale94dDHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days)111120DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)interleukin-2 (75000 U/d) (for 4 days)
15post-insult time of deathBDIX/OrlCrlmale81.7dDHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days)111121DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)Thymosin alpha-1 (200 ug/kg) (for 4 days)
16post-insult time of deathBDIX/OrlCrlmale80.5dDHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days) then sodium chloride solution (2 ml) (for 7 days)111142DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)sodium chloride solution (2 ml) (for 7 days)sodium chloride solution (2 ml) (for 7 days)
18post-insult time of deathBDIX/OrlCrlmale99.7dDHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days)111143DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)5-fluorouracil (100 mg/kg) (for 7 days)
18post-insult time of deathBDIX/OrlCrlmale101.3dDHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days)111144DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)interleukin-2 (75000 U/d) (for 4 days)5-fluorouracil (100 mg/kg) (for 7 days)interleukin-2 (75000 U/d) (for 4 days)
21post-insult time of deathBDIX/OrlCrlmale122.6dDHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days)111145DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)Thymosin alpha-1 (200 ug/kg) (for 4 days)interleukin-2 (75000 U/d) (for 4 days)5-fluorouracil (100 mg/kg) (for 7 days)Thymosin alpha-1 (200 ug/kg) (for 4 days)interleukin-2 (75000 U/d) (for 4 days)
13percentage of study population developing ascites during a period of timeBDIX/OrlCrlmale100%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days)111124DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)sodium chloride solution (2 ml) (for 7 days)
16percentage of study population developing extra-hepatic metastases during a period of timeBDIX/OrlCrlmale100%DHD/K12/TRb cells (9 X 10E6) and splenectomy then sodium chloride solution (2 ml) (for 7 days) then sodium chloride solution (2 ml) (for 7 days)111154DHD/K12/TRb cells (9 X 10E6) splenectomysodium chloride solution (2 ml) (for 7 days)sodium chloride solution (2 ml) (for 7 days)
18percentage of study population developing extra-hepatic metastases during a period of timeBDIX/OrlCrlmale89%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days)111155DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)5-fluorouracil (100 mg/kg) (for 7 days)
18percentage of study population developing extra-hepatic metastases during a period of timeBDIX/OrlCrlmale22%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days)111156DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)interleukin-2 (75000 U/d) (for 4 days)5-fluorouracil (100 mg/kg) (for 7 days)interleukin-2 (75000 U/d) (for 4 days)
21percentage of study population developing extra-hepatic metastases during a period of timeBDIX/OrlCrlmale9.5%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days)111157DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)Thymosin alpha-1 (200 ug/kg) (for 4 days)interleukin-2 (75000 U/d) (for 4 days)5-fluorouracil (100 mg/kg) (for 7 days)Thymosin alpha-1 (200 ug/kg) (for 4 days)interleukin-2 (75000 U/d) (for 4 days)
13post-insult time of deathBDIX/OrlCrlmale78.5dDHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days)111116DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)sodium chloride solution (2 ml) (for 7 days)
14post-insult time of deathBDIX/OrlCrlmale84dDHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days)111122DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)Thymosin alpha-1 (200 ug/kg) (for 4 days)interleukin-2 (75000 U/d) (for 4 days)
15post-insult time of deathBDIX/OrlCrlmale98.7dDHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days)111123DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)Thymosin alpha-1 (200 ug/kg) (for 4 days)interleukin-2 (75000 U/d) (for 4 days)
15percentage of study population developing ascites during a period of timeBDIX/OrlCrlmale100%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days)111125DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)
14percentage of study population developing ascites during a period of timeBDIX/OrlCrlmale100%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then Thymosin alpha-1 (200 ug/kg) (for 4 days)111126DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)Thymosin alpha-1 (200 ug/kg) (for 4 days)
15percentage of study population developing ascites during a period of timeBDIX/OrlCrlmale100%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then interleukin-2 (75000 U/d) (for 4 days)111127DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)interleukin-2 (75000 U/d) (for 4 days)
15percentage of study population developing ascites during a period of timeBDIX/OrlCrlmale53%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days)111128DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)interleukin-2 (75000 U/d) (for 4 days)
15percentage of study population developing ascites during a period of timeBDIX/OrlCrlmale100%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days)111129DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)Thymosin alpha-1 (200 ug/kg) (for 4 days)
14percentage of study population developing ascites during a period of timeBDIX/OrlCrlmale100%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days)111130DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)Thymosin alpha-1 (200 ug/kg) (for 4 days)interleukin-2 (75000 U/d) (for 4 days)
15percentage of study population developing ascites during a period of timeBDIX/OrlCrlmale13%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days)111131DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)Thymosin alpha-1 (200 ug/kg) (for 4 days)interleukin-2 (75000 U/d) (for 4 days)
13percentage of study population developing extra-hepatic metastases during a period of timeBDIX/OrlCrlmale100%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then sodium chloride solution (2 ml) (for 7 days)111132DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)sodium chloride solution (2 ml) (for 7 days)
15percentage of study population developing extra-hepatic metastases during a period of timeBDIX/OrlCrlmale93%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days)111133DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)
14percentage of study population developing extra-hepatic metastases during a period of timeBDIX/OrlCrlmale100%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then Thymosin alpha-1 (200 ug/kg) (for 4 days)111134DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)Thymosin alpha-1 (200 ug/kg) (for 4 days)
15percentage of study population developing extra-hepatic metastases during a period of timeBDIX/OrlCrlmale93%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then interleukin-2 (75000 U/d) (for 4 days)111135DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)interleukin-2 (75000 U/d) (for 4 days)
15percentage of study population developing extra-hepatic metastases during a period of timeBDIX/OrlCrlmale53%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days)111136DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)interleukin-2 (75000 U/d) (for 4 days)
15percentage of study population developing extra-hepatic metastases during a period of timeBDIX/OrlCrlmale87%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days)111137DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)Thymosin alpha-1 (200 ug/kg) (for 4 days)
14percentage of study population developing extra-hepatic metastases during a period of timeBDIX/OrlCrlmale100%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days)111138DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)Thymosin alpha-1 (200 ug/kg) (for 4 days)interleukin-2 (75000 U/d) (for 4 days)
15percentage of study population developing extra-hepatic metastases during a period of timeBDIX/OrlCrlmale13%DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy (for 0.1 hours) then 5-fluorouracil (100 mg/kg) (for 7 days) and Thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days)111139DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours)splenectomy (for 0.1 hours)5-fluorouracil (100 mg/kg) (for 7 days)Thymosin alpha-1 (200 ug/kg) (for 4 days)interleukin-2 (75000 U/d) (for 4 days)
49percentage of study population developing trigeminal nerve neurilemmomas during a period of timeBDIX.BDIV-D6Mit1-D6Mgh2/Ztefemale9.6%N-ethyl-N-nitrosourea (80 ug/g) 111211N-ethyl-N-nitrosourea (80 ug/g)
20percentage of study population developing trigeminal nerve neurilemmomas during a period of timeBDIX/Ifzfemale43.9%N-ethyl-N-nitrosourea (80 ug/g) 111208N-ethyl-N-nitrosourea (80 ug/g)
32percentage of study population developing trigeminal nerve neurilemmomas during a period of timeBDIV/lfzfemale0%N-ethyl-N-nitrosourea (80 ug/g) 111214N-ethyl-N-nitrosourea (80 ug/g)
37percentage of study population developing trigeminal nerve neurilemmomas during a period of timeBDIX/Ifzboth58%N-ethyl-N-nitrosourea (80 ug/g) 111206N-ethyl-N-nitrosourea (80 ug/g)
17percentage of study population developing trigeminal nerve neurilemmomas during a period of timeBDIX/Ifzmale72.9%N-ethyl-N-nitrosourea (80 ug/g) 111207N-ethyl-N-nitrosourea (80 ug/g)
100percentage of study population developing trigeminal nerve neurilemmomas during a period of timeBDIX.BDIV-D6Mit1-D6Mgh2/Zteboth23.8%N-ethyl-N-nitrosourea (80 ug/g) 111209N-ethyl-N-nitrosourea (80 ug/g)
51percentage of study population developing trigeminal nerve neurilemmomas during a period of timeBDIX.BDIV-D6Mit1-D6Mgh2/Ztemale38.2%N-ethyl-N-nitrosourea (80 ug/g) 111210N-ethyl-N-nitrosourea (80 ug/g)
77percentage of study population developing trigeminal nerve neurilemmomas during a period of timeBDIV/lfzboth0%N-ethyl-N-nitrosourea (80 ug/g) 111212N-ethyl-N-nitrosourea (80 ug/g)
45percentage of study population developing trigeminal nerve neurilemmomas during a period of timeBDIV/lfzmale0%N-ethyl-N-nitrosourea (80 ug/g) 111213N-ethyl-N-nitrosourea (80 ug/g)
9post-treatment survival time from doxorubicin-treated IgM immunocytomaLOU/MWslmale8drat IgM immunocytoma cells (1 x 10E4 cells) (between 17 and 21 days) then 0.9% sodium chloride solution109572rat IgM immunocytoma cells (1 x 10E4 cells) (between 17 and 21 days)0.9% sodium chloride solution
10post-treatment survival time from doxorubicin-treated IgM immunocytomaLOU/MWslmale23drat IgM immunocytoma cells (1 x 10E4 cells) (between 17 and 21 days) then doxorubicin (2 mg/kg) 109573rat IgM immunocytoma cells (1 x 10E4 cells) (between 17 and 21 days)doxorubicin (2 mg/kg)
10post-treatment survival time from doxorubicin-treated IgM immunocytomaLOU/MWslmale40drat IgM immunocytoma cells (1 x 10E4 cells) (between 17 and 21 days) then negatively charged liposome-entrapped doxorubicin (2 mg/kg) 109574rat IgM immunocytoma cells (1 x 10E4 cells) (between 17 and 21 days)negatively charged liposome-entrapped doxorubicin (2 mg/kg)
4ratio of deaths related to FUDR toxicity to total study population during a period of timeBDIX/HanHsdfemale0%DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with Hespan buffer (1 ml/min) (for 0.3 hours)111379DHD/K12/TRb - Sp-5 cells (1 X 10E6) isolated lung perfusion with Hespan buffer (1 ml/min) (for 0.3 hours)
7ratio of deaths related to FUDR toxicity to total study population during a period of timeBDIX/HanHsdfemale14%DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with floxuridine (7 mg/ml) (for 0.3 hours)111381DHD/K12/TRb - Sp-5 cells (1 X 10E6) isolated lung perfusion with floxuridine (7 mg/ml) (for 0.3 hours)
5ratio of deaths related to FUDR toxicity to total study population during a period of timeBDIX/HanHsdfemale20%DHD/K12/TRb - Sp-5 cells (1 X 10E6) then floxuridine (1 mg/kg/d) (for 7 days)111378DHD/K12/TRb - Sp-5 cells (1 X 10E6) floxuridine (1 mg/kg/d) (for 7 days)
5ratio of deaths related to FUDR toxicity to total study population during a period of timeBDIX/HanHsdfemale0%DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with floxuridine (3.5 mg/ml) (for 0.3 hours)111380DHD/K12/TRb - Sp-5 cells (1 X 10E6) isolated lung perfusion with floxuridine (3.5 mg/ml) (for 0.3 hours)
7ratio of deaths related to FUDR toxicity to total study population during a period of timeBDIX/HanHsdfemale14%DHD/K12/TRb - Sp-5 cells (1 X 10E6) then isolated lung perfusion with floxuridine (14 mg/ml) (for 0.3 hours)111382DHD/K12/TRb - Sp-5 cells (1 X 10E6) isolated lung perfusion with floxuridine (14 mg/ml) (for 0.3 hours)
3percentage of study population developing peritoneal carcinomatosis during a period of timeBDIX/OrlCrlmale0%phosphate buffered saline (0.2 ml) then phosphate buffered saline (0.1 ml) 111027phosphate buffered saline (0.2 ml) phosphate buffered saline (0.1 ml)
5percentage of study population developing peritoneal carcinomatosis during a period of timeBDIX/OrlCrlmale0%DHD/K12/TRb cells (1 X 10E6) 111028DHD/K12/TRb cells (1 X 10E6)
5percentage of study population developing peritoneal carcinomatosis during a period of timeBDIX/OrlCrlmale40%DHD/K12/TRb cells (2 X 10E6) 111029DHD/K12/TRb cells (2 X 10E6)
5percentage of study population developing peritoneal carcinomatosis during a period of timeBDIX/OrlCrlmale80%DHD/K12/TRb cells (3 X 10E6) 111030DHD/K12/TRb cells (3 X 10E6)
5percentage of study population developing peritoneal carcinomatosis during a period of timeBDIX/OrlCrlmale0%DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (0.5 X 10E6) 111031DHD/K12/TRb cells (1 X 10E6) DHD/K12/TRb cells (0.5 X 10E6)
5percentage of study population developing peritoneal carcinomatosis during a period of timeBDIX/OrlCrlmale0%DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1 X 10E6) 111032DHD/K12/TRb cells (1 X 10E6) DHD/K12/TRb cells (1 X 10E6)
5percentage of study population developing peritoneal carcinomatosis during a period of timeBDIX/OrlCrlmale40%DHD/K12/TRb cells (1 X 10E6) and DHD/K12/TRb cells (1.5 X 10E6) 111033DHD/K12/TRb cells (1 X 10E6) DHD/K12/TRb cells (1.5 X 10E6)
16number of fetuses with visceral malformations to total number of fetuses ratioWM/Nemboth33.3%trypan blue (40 mg/kg) 111288trypan blue (40 mg/kg)
28number of fetuses with visceral malformations to total number of fetuses ratioWM/Nemboth25.7%trypan blue (60 mg/kg) 111289trypan blue (60 mg/kg)
21number of fetuses with visceral malformations to total number of fetuses ratioWM/Nemboth31.5%trypan blue (120 mg/kg) 111290trypan blue (120 mg/kg)
51number of fetuses with visceral malformations to total number of fetuses ratioBDIX/Nemboth6.4%trypan blue (0 mg/kg) 111291trypan blue (0 mg/kg)
60number of fetuses with visceral malformations to total number of fetuses ratioBDIX/Nemboth2.8%trypan blue (60 mg/kg) 111292trypan blue (60 mg/kg)
32number of fetuses with visceral malformations to total number of fetuses ratioBDIX/Nemboth19.2%trypan blue (120 mg/kg) 111293trypan blue (120 mg/kg)
43number of fetuses with hydrocephaly to total number of fetuses ratioWM/Nemboth0%trypan blue (0 mg/kg) 111294trypan blue (0 mg/kg)
16number of fetuses with hydrocephaly to total number of fetuses ratioWM/Nemboth4.2%trypan blue (40 mg/kg) 111295trypan blue (40 mg/kg)
28number of fetuses with hydrocephaly to total number of fetuses ratioWM/Nemboth6.5%trypan blue (60 mg/kg) 111296trypan blue (60 mg/kg)
21number of fetuses with hydrocephaly to total number of fetuses ratioWM/Nemboth14.8%trypan blue (120 mg/kg) 111297trypan blue (120 mg/kg)
51number of fetuses with hydrocephaly to total number of fetuses ratioBDIX/Nemboth0%trypan blue (0 mg/kg) 111298trypan blue (0 mg/kg)
60number of fetuses with hydrocephaly to total number of fetuses ratioBDIX/Nemboth0%trypan blue (60 mg/kg) 111299trypan blue (60 mg/kg)
32number of fetuses with hydrocephaly to total number of fetuses ratioBDIX/Nemboth0%trypan blue (120 mg/kg) 111300trypan blue (120 mg/kg)
43number of fetuses with cardiovascular malformations to total number of fetuses ratioWM/Nemboth0%trypan blue (0 mg/kg) 111301trypan blue (0 mg/kg)
16number of fetuses with cardiovascular malformations to total number of fetuses ratioWM/Nemboth29.1%trypan blue (40 mg/kg) 111302trypan blue (40 mg/kg)
28number of fetuses with cardiovascular malformations to total number of fetuses ratioWM/Nemboth18%trypan blue (60 mg/kg) 111303trypan blue (60 mg/kg)
21number of fetuses with cardiovascular malformations to total number of fetuses ratioWM/Nemboth8.3%trypan blue (120 mg/kg) 111304trypan blue (120 mg/kg)
51number of fetuses with cardiovascular malformations to total number of fetuses ratioBDIX/Nemboth2.6%trypan blue (0 mg/kg) 111305trypan blue (0 mg/kg)
60number of fetuses with cardiovascular malformations to total number of fetuses ratioBDIX/Nemboth0%trypan blue (60 mg/kg) 111306trypan blue (60 mg/kg)
32number of fetuses with cardiovascular malformations to total number of fetuses ratioBDIX/Nemboth13.3%trypan blue (120 mg/kg) 111307trypan blue (120 mg/kg)
43number of fetuses with renal malformations to total number of fetuses ratioWM/Nemboth0%trypan blue (0 mg/kg) 111308trypan blue (0 mg/kg)
16number of fetuses with renal malformations to total number of fetuses ratioWM/Nemboth0%trypan blue (40 mg/kg) 111309trypan blue (40 mg/kg)
28number of fetuses with renal malformations to total number of fetuses ratioWM/Nemboth5.9%trypan blue (60 mg/kg) 111310trypan blue (60 mg/kg)
21number of fetuses with renal malformations to total number of fetuses ratioWM/Nemboth8.3%trypan blue (120 mg/kg) 111311trypan blue (120 mg/kg)
51number of fetuses with renal malformations to total number of fetuses ratioBDIX/Nemboth0%trypan blue (0 mg/kg) 111312trypan blue (0 mg/kg)
60number of fetuses with renal malformations to total number of fetuses ratioBDIX/Nemboth2.8%trypan blue (60 mg/kg) 111313trypan blue (60 mg/kg)
32number of fetuses with renal malformations to total number of fetuses ratioBDIX/Nemboth5.9%trypan blue (120 mg/kg) 111314trypan blue (120 mg/kg)
43number of fetuses with left umbilical artery to total number of fetuses ratioWM/Nemboth0%trypan blue (0 mg/kg) 111315trypan blue (0 mg/kg)
16number of fetuses with left umbilical artery to total number of fetuses ratioWM/Nemboth33.3%trypan blue (40 mg/kg) 111316trypan blue (40 mg/kg)
141number of fetuses with external malformations to total number of live fetuses ratioWM/Nemboth1.7%trypan blue (0 mg/kg) 111233trypan blue (0 mg/kg)
85number of fetuses with external malformations to total number of live fetuses ratioWM/Nemboth15.9%trypan blue (30 mg/kg) 111235trypan blue (30 mg/kg)
47number of fetuses with external malformations to total number of live fetuses ratioWM/Nemboth28.7%trypan blue (40 mg/kg) 111236trypan blue (40 mg/kg)
96number of fetuses with external malformations to total number of live fetuses ratioBDIX/Nemboth0%trypan blue (0 mg/kg) 111239trypan blue (0 mg/kg)
107number of fetuses with external malformations to total number of live fetuses ratioBDIX/Nemboth1.3%trypan blue (60 mg/kg) 111240trypan blue (60 mg/kg)
73number of fetuses with external malformations to total number of live fetuses ratioBDIX/Nemboth10.5%trypan blue (120 mg/kg) 111241trypan blue (120 mg/kg)
76number of fetuses with exencephaly to total number of live fetuses ratioWM/Nemboth0%trypan blue (20 mg/kg) 111243trypan blue (20 mg/kg)
85number of fetuses with exencephaly to total number of live fetuses ratioWM/Nemboth8.6%trypan blue (30 mg/kg) 111244trypan blue (30 mg/kg)
74number of fetuses with exencephaly to total number of live fetuses ratioWM/Nemboth13.9%trypan blue (60 mg/kg) 111246trypan blue (60 mg/kg)
50number of fetuses with exencephaly to total number of live fetuses ratioWM/Nemboth27%trypan blue (120 mg/kg) 111247trypan blue (120 mg/kg)
96number of fetuses with exencephaly to total number of live fetuses ratioBDIX/Nemboth0%trypan blue (0 mg/kg) 111248trypan blue (0 mg/kg)
107number of fetuses with exencephaly to total number of live fetuses ratioBDIX/Nemboth0%trypan blue (60 mg/kg) 111249trypan blue (60 mg/kg)
76number of fetuses with brain hernia to total number of live fetuses ratioWM/Nemboth2%trypan blue (20 mg/kg) 111252trypan blue (20 mg/kg)
85number of fetuses with brain hernia to total number of live fetuses ratioWM/Nemboth3.7%trypan blue (30 mg/kg) 111253trypan blue (30 mg/kg)
74number of fetuses with brain hernia to total number of live fetuses ratioWM/Nemboth10.9%trypan blue (60 mg/kg) 111255trypan blue (60 mg/kg)
50number of fetuses with brain hernia to total number of live fetuses ratioWM/Nemboth23%trypan blue (120 mg/kg) 111256trypan blue (120 mg/kg)
73number of fetuses with brain hernia to total number of live fetuses ratioBDIX/Nemboth0%trypan blue (120 mg/kg) 111259trypan blue (120 mg/kg)
12number of blastocysts implanted per litterWM/Nemboth12.1trypan blue (60 mg/kg) 111264trypan blue (60 mg/kg)
50number of fetuses with external malformations to total number of live fetuses ratioWM/Nemboth53.2%trypan blue (120 mg/kg) 111238trypan blue (120 mg/kg)
47number of fetuses with exencephaly to total number of live fetuses ratioWM/Nemboth15.8%trypan blue (40 mg/kg) 111245trypan blue (40 mg/kg)
73number of fetuses with exencephaly to total number of live fetuses ratioBDIX/Nemboth0%trypan blue (120 mg/kg) 111250trypan blue (120 mg/kg)
141number of fetuses with brain hernia to total number of live fetuses ratioWM/Nemboth0%trypan blue (0 mg/kg) 111251trypan blue (0 mg/kg)
47number of fetuses with brain hernia to total number of live fetuses ratioWM/Nemboth10%trypan blue (40 mg/kg) 111254trypan blue (40 mg/kg)
96number of fetuses with brain hernia to total number of live fetuses ratioBDIX/Nemboth0%trypan blue (0 mg/kg) 111257trypan blue (0 mg/kg)
107number of fetuses with brain hernia to total number of live fetuses ratioBDIX/Nemboth0%trypan blue (60 mg/kg) 111258trypan blue (60 mg/kg)
13number of blastocysts implanted per litterWM/Nemboth12.6control condition111260control condition
11number of blastocysts/embryos lost postimplantation to litter size ratioWM/Nemboth58.6%trypan blue (40 mg/kg) 111272trypan blue (40 mg/kg)
10number of blastocysts/embryos lost postimplantation to litter size ratioWM/Nemboth51.6%trypan blue (120 mg/kg) 111274trypan blue (120 mg/kg)
13number of blastocysts/embryos lost postimplantation to litter size ratioBDIX/Nemboth21.6%control condition111275control condition
141number of fetuses with eye malformations to total number of live fetuses ratioWM/Nemboth0%trypan blue (0 mg/kg) 111278trypan blue (0 mg/kg)
76number of fetuses with eye malformations to total number of live fetuses ratioWM/Nemboth2%trypan blue (20 mg/kg) 111279trypan blue (20 mg/kg)
76number of fetuses with external malformations to total number of live fetuses ratioWM/Nemboth2%trypan blue (20 mg/kg) 111234trypan blue (20 mg/kg)
74number of fetuses with external malformations to total number of live fetuses ratioWM/Nemboth45.5%trypan blue (60 mg/kg) 111237trypan blue (60 mg/kg)
141number of fetuses with exencephaly to total number of live fetuses ratioWM/Nemboth0%trypan blue (0 mg/kg) 111242trypan blue (0 mg/kg)
12number of blastocysts implanted per litterWM/Nemboth12.8trypan blue (30 mg/kg) 111262trypan blue (30 mg/kg)
11number of blastocysts implanted per litterWM/Nemboth10.5trypan blue (40 mg/kg) 111263trypan blue (40 mg/kg)
14number of blastocysts implanted per litterBDIX/Nemboth9.4trypan blue (120 mg/kg) 111268trypan blue (120 mg/kg)
13number of blastocysts/embryos lost postimplantation to litter size ratioWM/Nemboth13%control condition111269control condition
12number of blastocysts/embryos lost postimplantation to litter size ratioWM/Nemboth51.5%trypan blue (60 mg/kg) 111273trypan blue (60 mg/kg)
107number of fetuses with eye malformations to total number of live fetuses ratioBDIX/Nemboth1.3%trypan blue (60 mg/kg) 111285trypan blue (60 mg/kg)
10number of blastocysts implanted per litterWM/Nemboth12.9trypan blue (120 mg/kg) 111265trypan blue (120 mg/kg)
13number of blastocysts implanted per litterBDIX/Nemboth9.2control condition111266control condition
16number of blastocysts implanted per litterBDIX/Nemboth10.5trypan blue (60 mg/kg) 111267trypan blue (60 mg/kg)
10number of blastocysts/embryos lost postimplantation to litter size ratioWM/Nemboth33.3%trypan blue (20 mg/kg) 111270trypan blue (20 mg/kg)
12number of blastocysts/embryos lost postimplantation to litter size ratioWM/Nemboth43.4%trypan blue (30 mg/kg) 111271trypan blue (30 mg/kg)
16number of blastocysts/embryos lost postimplantation to litter size ratioBDIX/Nemboth34.8%trypan blue (60 mg/kg) 111276trypan blue (60 mg/kg)
14number of blastocysts/embryos lost postimplantation to litter size ratioBDIX/Nemboth44.9%trypan blue (120 mg/kg) 111277trypan blue (120 mg/kg)
85number of fetuses with eye malformations to total number of live fetuses ratioWM/Nemboth5.2%trypan blue (30 mg/kg) 111280trypan blue (30 mg/kg)
47number of fetuses with eye malformations to total number of live fetuses ratioWM/Nemboth0%trypan blue (40 mg/kg) 111281trypan blue (40 mg/kg)
74number of fetuses with eye malformations to total number of live fetuses ratioWM/Nemboth26.1%trypan blue (60 mg/kg) 111282trypan blue (60 mg/kg)
50number of fetuses with eye malformations to total number of live fetuses ratioWM/Nemboth19.5%trypan blue (120 mg/kg) 111283trypan blue (120 mg/kg)
96number of fetuses with eye malformations to total number of live fetuses ratioBDIX/Nemboth0%trypan blue (0 mg/kg) 111284trypan blue (0 mg/kg)
73number of fetuses with eye malformations to total number of live fetuses ratioBDIX/Nemboth9.6%trypan blue (120 mg/kg) 111286trypan blue (120 mg/kg)
28number of fetuses with left umbilical artery to total number of fetuses ratioWM/Nemboth22%trypan blue (60 mg/kg) 111317trypan blue (60 mg/kg)
96number of fetuses with skeletal malformations to total number of fetuses ratioWM/Nemboth0%trypan blue (0 mg/kg) 111322trypan blue (0 mg/kg)
30number of fetuses with skeletal malformations to total number of fetuses ratioWM/Nemboth16%trypan blue (40 mg/kg) 111323trypan blue (40 mg/kg)
46number of fetuses with skeletal malformations to total number of fetuses ratioWM/Nemboth12.1%trypan blue (60 mg/kg) 111324trypan blue (60 mg/kg)
29number of fetuses with skeletal malformations to total number of fetuses ratioWM/Nemboth24.1%trypan blue (120 mg/kg) 111325trypan blue (120 mg/kg)
45number of fetuses with skeletal malformations to total number of fetuses ratioBDIX/Nemboth0%trypan blue (0 mg/kg) 111326trypan blue (0 mg/kg)
47number of fetuses with skeletal malformations to total number of fetuses ratioBDIX/Nemboth0%trypan blue (60 mg/kg) 111327trypan blue (60 mg/kg)
31number of fetuses with skeletal malformations to total number of fetuses ratioBDIX/Nemboth6.7%trypan blue (120 mg/kg) 111328trypan blue (120 mg/kg)
96number of fetuses with cranial malformations to total number of fetuses ratioWM/Nemboth0%trypan blue (0 mg/kg) 111329trypan blue (0 mg/kg)
30number of fetuses with cranial malformations to total number of fetuses ratioWM/Nemboth7.6%trypan blue (40 mg/kg) 111330trypan blue (40 mg/kg)
46number of fetuses with cranial malformations to total number of fetuses ratioWM/Nemboth9.4%trypan blue (60 mg/kg) 111331trypan blue (60 mg/kg)
29number of fetuses with cranial malformations to total number of fetuses ratioWM/Nemboth13.3%trypan blue (120 mg/kg) 111332trypan blue (120 mg/kg)
45number of fetuses with cranial malformations to total number of fetuses ratioBDIX/Nemboth0%trypan blue (0 mg/kg) 111333trypan blue (0 mg/kg)
47number of fetuses with cranial malformations to total number of fetuses ratioBDIX/Nemboth0%trypan blue (60 mg/kg) 111334trypan blue (60 mg/kg)
31number of fetuses with cranial malformations to total number of fetuses ratioBDIX/Nemboth3.3%trypan blue (120 mg/kg) 111335trypan blue (120 mg/kg)
96number of fetuses with vertebral malformations to total number of fetuses ratioWM/Nemboth0%trypan blue (0 mg/kg) 111336trypan blue (0 mg/kg)
30number of fetuses with vertebral malformations to total number of fetuses ratioWM/Nemboth8.3%trypan blue (40 mg/kg) 111337trypan blue (40 mg/kg)
46number of fetuses with vertebral malformations to total number of fetuses ratioWM/Nemboth16.3%trypan blue (60 mg/kg) 111338trypan blue (60 mg/kg)
29number of fetuses with vertebral malformations to total number of fetuses ratioWM/Nemboth15%trypan blue (120 mg/kg) 111339trypan blue (120 mg/kg)
45number of fetuses with vertebral malformations to total number of fetuses ratioBDIX/Nemboth0%trypan blue (0 mg/kg) 111340trypan blue (0 mg/kg)
47number of fetuses with vertebral malformations to total number of fetuses ratioBDIX/Nemboth0%trypan blue (60 mg/kg) 111341trypan blue (60 mg/kg)
31number of fetuses with vertebral malformations to total number of fetuses ratioBDIX/Nemboth3.3%trypan blue (120 mg/kg) 111342trypan blue (120 mg/kg)
96number of fetuses with sternum variations to total number of fetuses ratioWM/Nemboth0%trypan blue (0 mg/kg) 111343trypan blue (0 mg/kg)
30number of fetuses with sternum variations to total number of fetuses ratioWM/Nemboth4.2%trypan blue (40 mg/kg) 111344trypan blue (40 mg/kg)
46number of fetuses with sternum variations to total number of fetuses ratioWM/Nemboth8.3%trypan blue (60 mg/kg) 111345trypan blue (60 mg/kg)
29number of fetuses with sternum variations to total number of fetuses ratioWM/Nemboth0%trypan blue (120 mg/kg) 111346trypan blue (120 mg/kg)
45number of fetuses with sternum variations to total number of fetuses ratioBDIX/Nemboth0%trypan blue (0 mg/kg) 111347trypan blue (0 mg/kg)
47number of fetuses with sternum variations to total number of fetuses ratioBDIX/Nemboth1.7%trypan blue (60 mg/kg) 111348trypan blue (60 mg/kg)
31number of fetuses with sternum variations to total number of fetuses ratioBDIX/Nemboth10.8%trypan blue (120 mg/kg) 111349trypan blue (120 mg/kg)
96number of fetuses with cervical rib variations to total number of fetuses ratioWM/Nemboth0%trypan blue (0 mg/kg) 111350trypan blue (0 mg/kg)
30number of fetuses with cervical rib variations to total number of fetuses ratioWM/Nemboth1.4%trypan blue (40 mg/kg) 111351trypan blue (40 mg/kg)
46number of fetuses with cervical rib variations to total number of fetuses ratioWM/Nemboth0%trypan blue (60 mg/kg) 111352trypan blue (60 mg/kg)
29number of fetuses with cervical rib variations to total number of fetuses ratioWM/Nemboth0%trypan blue (120 mg/kg) 111353trypan blue (120 mg/kg)
45number of fetuses with cervical rib variations to total number of fetuses ratioBDIX/Nemboth0%trypan blue (0 mg/kg) 111354trypan blue (0 mg/kg)
47number of fetuses with cervical rib variations to total number of fetuses ratioBDIX/Nemboth0%trypan blue (60 mg/kg) 111355trypan blue (60 mg/kg)
31number of fetuses with cervical rib variations to total number of fetuses ratioBDIX/Nemboth0%trypan blue (120 mg/kg) 111356trypan blue (120 mg/kg)
96number of fetuses with lumbar rib variations to total number of fetuses ratioWM/Nemboth0%trypan blue (0 mg/kg) 111357trypan blue (0 mg/kg)
30number of fetuses with lumbar rib variations to total number of fetuses ratioWM/Nemboth12.5%trypan blue (40 mg/kg) 111358trypan blue (40 mg/kg)
46number of fetuses with lumbar rib variations to total number of fetuses ratioWM/Nemboth20.8%trypan blue (60 mg/kg) 111359trypan blue (60 mg/kg)
29number of fetuses with lumbar rib variations to total number of fetuses ratioWM/Nemboth41.7%trypan blue (120 mg/kg) 111360trypan blue (120 mg/kg)
45number of fetuses with lumbar rib variations to total number of fetuses ratioBDIX/Nemboth0%trypan blue (0 mg/kg) 111361trypan blue (0 mg/kg)
47number of fetuses with lumbar rib variations to total number of fetuses ratioBDIX/Nemboth0%trypan blue (60 mg/kg) 111362trypan blue (60 mg/kg)
31number of fetuses with lumbar rib variations to total number of fetuses ratioBDIX/Nemboth0%trypan blue (120 mg/kg) 111363trypan blue (120 mg/kg)
96number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratioWM/Nemboth0%trypan blue (0 mg/kg) 111364trypan blue (0 mg/kg)
30number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratioWM/Nemboth0%trypan blue (40 mg/kg) 111365trypan blue (40 mg/kg)
46number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratioWM/Nemboth0%trypan blue (60 mg/kg) 111366trypan blue (60 mg/kg)
29number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratioWM/Nemboth0%trypan blue (120 mg/kg) 111367trypan blue (120 mg/kg)
45number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratioBDIX/Nemboth44.6%trypan blue (0 mg/kg) 111368trypan blue (0 mg/kg)
47number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratioBDIX/Nemboth22.2%trypan blue (60 mg/kg) 111369trypan blue (60 mg/kg)
31number of fetuses with an ossified anterior arch of atlas to total number of fetuses ratioBDIX/Nemboth28.3%trypan blue (120 mg/kg) 111370trypan blue (120 mg/kg)
96number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratioWM/Nemboth28.7%trypan blue (0 mg/kg) 111371trypan blue (0 mg/kg)
30number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratioWM/Nemboth57.8%trypan blue (40 mg/kg) 111372trypan blue (40 mg/kg)
46number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratioWM/Nemboth67.6%trypan blue (60 mg/kg) 111373trypan blue (60 mg/kg)
29number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratioWM/Nemboth85%trypan blue (120 mg/kg) 111374trypan blue (120 mg/kg)
45number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratioBDIX/Nemboth8.2%trypan blue (0 mg/kg) 111375trypan blue (0 mg/kg)
47number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratioBDIX/Nemboth14.1%trypan blue (60 mg/kg) 111376trypan blue (60 mg/kg)
31number of fetuses without an ossified first cervical vertebral body to total number of fetuses ratioBDIX/Nemboth51.7%trypan blue (120 mg/kg) 111377trypan blue (120 mg/kg)
10number of blastocysts implanted per litterWM/Nemboth11.4trypan blue (20 mg/kg) 111261trypan blue (20 mg/kg)
43number of fetuses with visceral malformations to total number of fetuses ratioWM/Nemboth0%trypan blue (0 mg/kg) 111287trypan blue (0 mg/kg)
21number of fetuses with left umbilical artery to total number of fetuses ratioWM/Nemboth33.3%trypan blue (120 mg/kg) 111318trypan blue (120 mg/kg)
51number of fetuses with left umbilical artery to total number of fetuses ratioBDIX/Nemboth1.5%trypan blue (0 mg/kg) 111319trypan blue (0 mg/kg)
60number of fetuses with left umbilical artery to total number of fetuses ratioBDIX/Nemboth6.8%trypan blue (60 mg/kg) 111320trypan blue (60 mg/kg)
32number of fetuses with left umbilical artery to total number of fetuses ratioBDIX/Nemboth20.5%trypan blue (120 mg/kg) 111321trypan blue (120 mg/kg)
6post-insult time of death due to metastatic liver tumorsBDIX/OrlIcomale114dPRObR1 cells (2 x 10E6 cells) then phosphate buffered saline (1 ml) (for 7 days)107418PRObR1 cells (2 x 10E6 cells) phosphate buffered saline (1 ml) (for 7 days)
6post-insult time of death due to metastatic liver tumorsBDIX/OrlIcomale34dPROb cells (2 x 10E6 cells) then phosphate buffered saline (1 ml) (for 7 days)107419PROb cells (2 x 10E6 cells) phosphate buffered saline (1 ml) (for 7 days)
6post-insult time of death due to metastatic liver tumorsBDIX/OrlIcomale66dPROb cells (2 x 10E6 cells) then sodium butyrate (20 mmol/l) (for 7 days) and interleukin-2 (45 x 10E4 IU/kg) (for 5 days)107420PROb cells (2 x 10E6 cells) sodium butyrate (20 mmol/l) (for 7 days)interleukin-2 (45 x 10E4 IU/kg) (for 5 days)
16metastatic intraperitoneal tumor weightWAG/OlaHsdmale7.42gCC531 cells (5 X 10E6) (for 21 days) then vehicle control condition (1 ml) (for 21 days)107874CC531 cells (5 X 10E6) (for 21 days)vehicle control condition (1 ml) (for 21 days)
16metastatic intraperitoneal tumor weightWAG/OlaHsdmale3.22gCC531 cells (5 X 10E6) (for 21 days) then phosphoramidon (250 mg) (for 21 days)107875CC531 cells (5 X 10E6) (for 21 days)phosphoramidon (250 mg) (for 21 days)
N/Apercentage of study population developing meconium ileus during a period of timeSD-Cftrem2Apbnot specified40%controlled ColonLYTELY content drinking water (4.5 %) (for 7 days)111464controlled ColonLYTELY content drinking water (4.5 %) (for 7 days)
N/Apercentage of study population developing meconium ileus during a period of timeSD-Cftrem1Apbnot specified16%control condition111463control condition